Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, single-arm phase Ⅱ study aiming to evaluate the
efficacy and safety profile of above-mentioned combination strategy in first-line
therapy-failed advanced pancreatic cancer. Totally 53 patients with locally advanced or
metastatic pancreatic cancer are to be enrolled and receive anlotinib plus toripalimab and
nab-paclitaxel.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University